EFFECT OF CENTRAL SENSITIZATION ON DISEASE SEVERITY AND QUALITY OF LIFE IN FIBROMYALGIA SYNDROME

Yıl 2025, Cilt: 8 Sayı: 2, 111 - 122

Esra Akın , İsmail Saracoglu , Merve Akdeniz Leblebicier

https://doi.org/10.52538/iduhes.1730818

Öz

The negative effects of central sensitization on various chronic painful conditions are known. However, there is no study that has investigated the clinical effects of central sensitization in Fibromyalgia Syndrome (FMS) in detail. The aim of our study was to investigate the effects of central sensitization on disease severity and quality of life in FMS. Within the framework of this purpose, 51 individuals with FMS were included in the study. Individuals with FMS were divided into subgroups according to their Central Sensitization Inventory (CSI) scores. The disease severity of all individuals was measured using the Revised Fibromyalgia Questionnaire. Their quality of life was measured using the Short Form-12 Health Survey. As a result of the grouping, 3 of the individuals with FMS had subclinical, 6 had mild, 11 had moderate, 13 had severe, and 18 had very severe central sensitization. When these groups were investigated, significant differences were found between the mild-very severe and subclinical-very severe groups in terms of disease severity and mental component of quality of life (p<0.05). No difference was found between the other groups (p<0.05). These findings show that central sensitization has an important place in FMS and other chronic painful disorders. Therefore, it is thought that more effective treatment can be provided by considering central sensitization in the assessment. Individual and multimodal methods are among the main treatment strategies recommended for the management of central sensitization. In future studies, the effects of these treatment strategies on central sensitization can be investigated.

Anahtar Kelimeler

Pain , Chronic Pain , Central Sensitization , Fibromyalgia Syndrome

Etik Beyan

This study was approved by the Kütahya Health Sciences University, Non-Interventional Clinical Research Ethics Committee with the decision numbered 2025/07-10 dated 29.05.2025.

Destekleyen Kurum

None.

FİBROMİYALJİ SENDROMUNDA SANTRAL SENSİTİZASYONUN HASTALIK ŞİDDETİ VE YAŞAM KALİTESİ ÜZERİNDEKİ ETKİSİ

Öz

Santral sensitizasyonun farklı kronik ağrılı durumlardaki olumsuz etkisi bilinmektedir. Buna rağmen santral sensitizasyonun Fibromiyalji Sendromu’nda (FMS) klinik etkilerini detaylı olarak inceleyen herhangi bir çalışma bulunmamaktadır. Çalışmamızın amacı, FMS’de santral sensitizasyonun hastalık şiddeti ve yaşam kalitesi üzerindeki etkisini incelemektir. Bu amaç çerçevesinde, çalışmaya 51 FMS’li birey dahil edildi. FMS’li bireyler, Santral Sensitizasyon Envanteri (SSE) puanlarına göre alt gruplara ayrıldı. Tüm bireylerin hastalık şiddetleri Revize Fibromiyalji Anketi kullanılarak ölçüldü. Yaşam kaliteleri ise Kısa Form-12 Sağlık Anketi ile ölçüldü. Yapılan gruplandırma sonucunda, FMS’li bireylerden 3’ü subklinik, 6’sı hafif, 11’i orta, 13’ü şiddetli ve 18’i ise çok şiddetli seviyede santral sensitizasyona sahipti. Bu gruplar incelendiğinde, hafif-çok şiddetli ve subklinik-çok şiddetli seviyedeki gruplar arasında hastalık şiddeti bakımından ve yaşam kalitesinin mental bileşeni bakımından anlamlı farklılıklar tespit edildi (p<0,05). Diğer gruplar arasında bir farklılığa rastlanılmadı (p<0,05). Bu bulgular, santral sensitizasyonun FMS’de ve diğer kronik ağrılı rahatsızlıklarında önemli bir yeri olduğunu göstermektedir. Bu nedenle değerlendirmede santral sensitizasyonun dikkate alınması ile daha etkin tedavinin sağlanabileceği düşünülmektedir. Santral sensitizasyonun yönetiminde önerilen başlıca tedavi stratejileri arasında bireysel ve multimodal yöntemler yer almaktadır. Gelecekteki çalışmalarda, bu tedavi stratejilerinin santral sensitizasyon üzerindeki etkileri incelenebilir.

Anahtar Kelimeler

Ağrı , Kronik Ağrı , Santral Sensitizasyon , Fibromiyalji Sendromu

Etik Beyan

Bu çalışma, Kütahya Sağlık Bilimleri Üniversitesi, Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu Başkanlığı, 29.05.2025 tarihli ve 2025/07-10 numaralı karar ile onaylandı

Destekleyen Kurum

Yoktur.

Kaynakça

• 1. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: pathogenesis, mechanisms, diagnosis and treatment options update. International journal of molecular sciences 2021; 22(8):3891. doi:10.3390/ijms22083891.
• 2. Kocyigit BF, Akyol A. Fibromyalgia syndrome: epidemiology, diagnosis and treatment. Reumatologia 2022; 60(6):413-21. doi:10.5114/reum.2022.123671.
• 3. Lee SG, Kim GT. Etiopathogenesis of fibromyalgia. Journal of electrodiagnosis and neuromuscular diseases 2023; 25(1):1-18. doi:10.18214/jend.2022.00227
• 4. Guler MA, Celik OF, Ayhan FF. The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases. Clinical rheumatology 2020; 39:269-74. doi:10.1007/s10067-019-04749-1.
• 5. Nijs J, George SZ, Clauw DJ, Fernández-de-Las-Peñas C, Kosek E, Ickmans K, Fernández-Carnero J, Polli A, Kapreli E, Huymans E, Cuesta-Vargas AI, Mani R, Lundberg M, Leysen L, Rice D, Sterling M, Curatolo M. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. The lancet rheumatology 2021; 3(5):e383-e92. doi:10.1016/S2665-9913(21)00032-1.
• 6. Aykurt Karlıbel I, Kasapoğlu Aksoy M. The relationship between central sensitization and disease activity, quality of life, and sleep quality among patients with axial spondyloarthritis. Irish journal of medical science 2023; 192(1):481-9. doi:10.1007/s11845-022-02957-4.
• 7. Salaffi F, Farah S, Bianchi B, Di Carlo M. Central sensitization in psoriatic arthritis: relationship with composite measures of disease activity, functional disability, and health-related quality of life. The journal of rheumatology 2024; 51(2):144-9. doi:10.3899/jrheum.2023-0177.
• 8. Sariyildiz A, Coskun Benlidayi I, Yetişir A, Turk I, Zengin Acemoglu SS, Deniz V. Central sensitization significantly deteriorates functionality and the interpretation of self-reported disease activity in primary Sjögren’s syndrome. Clinical rheumatology 2024; 43(6):1949-58. doi:10.1007/s10067-024-06981-w.
• 9. Akeda K, Takegami N, Yamada J, Fujiwara T, Nishimura A, Sudo A. Central sensitization in chronic low back pain: a population-based study of a Japanese mountain village. Journal of pain research 2021; 14:1271-80. doi:10.2147/JPR.S301924.
• 10. Koh IJ, Kang BM, Kim MS, Choi KY, Sohn S, In Y. How does preoperative central sensitization affect quality of life following total knee arthroplasty?. The journal of arthroplasty 2020; 35(8):2044-49. doi:10.1016/j.arth.2020.04.004.
• 11. Volcheck MM, Graham SM, Fleming KC, Mohabbat AB, Luedtke CA. Central sensitization, chronic pain, and other symptoms: better understanding, better management. Cleveland clinic journal of medicine 2023; 90(4):245-54. doi:10.3949/ccjm.90a.22019.
• 12. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt, B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in arthritis and rheumatism 2016; 46(3):319-29. doi:10.1016/j.semarthrit.2016.08.012.
• 13. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the central sensitization inventory. Pain practice 2017; 17(2):166-75. doi:10.1111/papr.12440.
• 14. Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, Perez Y, Gatchel RJ. The development and psychometric validation of the central sensitization inventory. Pain practice 2012; 12(4):276-85. doi:10.1111/j.1533-2500.2011.00493.x.
• 15. Keleş ED, Birtane M, Ekuklu G, Kılınçer C, Çalıyurt O, Taştekin N, Is EE, Ketenci A, Neblett R. Validity and reliability of the Turkish version of the central sensitization inventory. Archives of rheumatology 2021; 36(4):518-26. doi:10.46497/ArchRheumatol.2022.8665.
• 16. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The revised fibromyalgia impact questionnaire (FIQR): validation and psychometric properties. Arthritis research therapy 2009; 11(4):1-14. doi:10.1186/ar2783.
• 17. Ediz L, Hiz O, Toprak M, Tekeoglu I, Ercan S. The validity and reliability of the Turkish version of the Revised Fibromyalgia Impact Questionnaire. Clinical rheumatology 2011; 30:339-46. doi:10.1007/s10067-010-1546-8.
• 18. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical care 1996; 34(3):220-33. doi:10.1097/00005650-199603000-00003.
• 19. Soylu C, Kütük B. Reliability and validity of the Turkish version of SF-12 Health Survey. Turkish journal of psychiatry 2022; 33(2):108-17. doi:10.5080/u25700.
• 20. Kieskamp SC, Paap D, Carbo MJ, Wink F, Bos R, Bootsma H, Arends S, Spoorenberg A. Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. Rheumatology 2021; 60(10):4476-85. doi:10.1093/rheumatology/keab019.
• 21. Yücel FN, Gezer HH, Jandaulyet J, Öz N, Acer Kasman S, Duruöz MT. Clinical and functional impact of central sensitization on patients with familial Mediterranean fever: a cross-sectional study. Rheumatology International 2023; 43(1):125-36. doi:10.1007/s00296-022-05181-6.
• 22. Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. Journal of applied biobehavioral research 2018; 23(2):e12137. doi:10.1111/jabr.12137.
• 23. Kieskamp SC, Paap D, Carbo MJ, Wink F, Bos R, Bootsma H, Arends S, Spoorenberg A. Central sensitization has major impact on quality of life in patients with axial spondyloarthritis. Seminars in arthritis and rheumatism 2022; 52:151933. doi:10.1016/j.semarthrit.2021.11.006.
• 24. Lall DD, Gupta R, Dadu N, Jain A. Impact of central sensitization on pain intensity, pain-related symptoms, and health-related quality of life in chronic pain outpatient department. Indian journal of pain 2021; 35(3):203-08. doi:10.4103/ijpn.ijpn_161_20.
• 25. Marques ES, Meziat Filho NA, Gouvea ME, Ferreira PS, Nogueira LA. Functionality, psychosocial factors and quality of life in women with predominance of central sensitization. Revista Dor 2017; 18(02):112-18. doi:10.5935/1806-0013.20170023.
• 26. Manfuku M, Nishigami T, Mibu A, Tanaka K, Kitagaki K, Sumiyoshi K. Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls. Breast cancer 2019; 26:758-65. doi:10.1007/s12282-019-00979-y.
• 27. Adams LM, Turk DC. Central sensitization and the biopsychosocial approach to understanding pain. Journal of applied biobehavioral research 2018; 23(2):e12125. doi:10.1111/jabr.12125.